miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 2, 2016, Pages 204-216

  Xiao, Junjie ^a   Bei, Yihua ^a   Liu, Jingqi ^b   Dimitrova Shumkovska, Jasmina ^a,c   Kuang, Dapeng ^b   Zhou, Qiulian ^a   Li, Jin ^a   Yang, Yanning ^b   Xiang, Yang ^d   Wang, Fei ^b   Yang, Changqing ^b   Yang, Wenzhuo ^b  

^a SHANGHAI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^d NANJING UNIVERSITY   (China)

Author keywords

NAFLD; Exercise; FGF 21; miR 212; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FIBROBLAST GROWTH FACTOR 21; LONG CHAIN FATTY ACID; MICRORNA 122 3P; MICRORNA 1224 5P; MICRORNA 1249 5P; MICRORNA 132 3P; MICRORNA 149; MICRORNA 149 5P; MICRORNA 155; MICRORNA 155 5P; MICRORNA 1948 3P; MICRORNA 200A 3P; MICRORNA 200B 3P; MICRORNA 205 5P; MICRORNA 212; MICRORNA 212 3P; MICRORNA 31 3P; MICRORNA 346 3P; MICRORNA 34A; MICRORNA 34A 5P; MICRORNA 350 3P; MICRORNA 505 5P; MICRORNA 5100; MICRORNA 541 5P; MICRORNA 592 5P; MICRORNA 674 3P; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; FATTY ACID; FIBROBLAST GROWTH FACTOR; MESSENGER RNA; MICRORNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; EXERCISE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIPID DIET; LIPID METABOLISM; LIPOGENESIS; LIVER INJURY; MALE; MICROARRAY ANALYSIS; MOUSE; NILE RED STAINING; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STAINING; UPREGULATION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; GENETICS; HEP-G2 CELL LINE; LIVER; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DIET, HIGH-FAT; DOWN-REGULATION; FATTY ACIDS; FIBROBLAST GROWTH FACTORS; HEP G2 CELLS; HUMANS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSICAL CONDITIONING, ANIMAL; RNA, MESSENGER;

EID: 84955686866     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12733     Document Type: Article

References (67)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011; 332: 1519-23.
2. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010; 5: 145-71.
3. Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol. 2014; 6: 800-11.
4. Gerber L, Otgonsuren M, Mishra A, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther. 2012; 36: 772-81.
5. Rector RS, Uptergrove GM, Morris EM, et al. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. Am J Physiol Gastrointest Liver Physiol. 2011; 300: G874-83.
6. Cho J, Kim S, Lee S, et al. Effect of training intensity on nonalcoholic fatty liver disease. Med Sci Sports Exerc. 2015; 47: 1624-34.
7. Pugh CJ, Spring VS, Kemp GJ, et al. Exercise training reverses endothelial dysfunction in nonalcoholic fatty liver disease. Am J Physiol Heart Circ Physiol. 2014; 307: H1298-306.
8. Arias-Loste MT, Ranchal I, Romero-Gómez M, et al. Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci. 2014; 15: 23163-78.
9. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology. 2008; 48: 1791-8.
10. Ordonez R, Carbajo-Pescador S, Mauriz JL, et al. Understanding nutritional interventions and physical exercise in non-alcoholic Fatty liver disease. Curr Mol Med. 2015; 15: 3-26.
11. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011; 60: 1278-83.
12. Bacchi E, Negri C, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology. 2013; 58: 1287-95.
13. Zelber-Sagi S, Buch A, Yeshua H, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol. 2014; 20: 4382-92.
14. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433: 769-73.
15. Van Rooij E. The art of microRNA research. Circ Res. 2011; 108: 219-34.
16. Ceccarelli S, Panera N, Gnani D, et al. Dual role of microRNAs in NAFLD. Int J Mol Sci. 2013; 14: 8437-55.
17. Panera N, Gnani D, Crudele A, et al. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20: 15079-86.
18. Kurtz CL, Fannin EE, Toth CL, et al. Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Sci Rep. 2015; 5: 12911.
19. Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015; 64: 800-12.
20. Bhatia H, Verma G, Datta M. miR-107 orchestrates ER stress induction and lipid accumulation by post-transcriptional regulation of fatty acid synthase in hepatocytes. Biochim Biophys Acta. 2014; 1839: 334-43.
21. Li S, Chen X, Zhang H, et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res. 2009; 50: 1756-65.
22. Pandey AK, Verma G, Vig S, et al. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol. 2011; 332: 125-33.
23. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011; 474: 649-53.
24. Zhong D, Huang G, Zhang Y, et al. MicroRNA-1 and microRNA-206 suppress LXRα-induced lipogenesis in hepatocytes. Cell Signal. 2013; 25: 1429-37.
25. Miller AM, Gilchrist DS, Nijjar J, et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One. 2013; 8: e72324.
26. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007; 13: 613-8.
27. Lin RC, Weeks KL, Gao XM, et al. PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol. 2010; 30: 724-32.
28. Lund J, Hafstad AD, Boardman NT, et al. Exercise training promotes cardioprotection through oxygen-sparing action in high-fat fed mice. Am J Physiol Heart Circ Physiol. 2015; 308: H823-9.
29. Martinelli NC, Cohen CR, Santos KG, et al. An analysis of the global expression of microRNAs in an experimental model of physiological left ventricular hypertrophy. PLoS One. 2014; 9: e93271.
30. Ooi JY, Bernardo BC, McMullen JR. The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy. Future Med Chem. 2014; 6: 205-22.
31. Soci UP, Fernandes T, Hashimoto NY, et al. MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. Physiol Genomics. 2011; 43: 665-73.
32. Stevens JW, Khunti K, Harvey R, et al. Preventing the progression to Type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. Diabetes Res Clin Pract. 2015; 107: 320-31.
33. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012; 12: 20.
34. Cintra DE, Ropelle ER, Vitto MF, et al. Reversion of hepatic steatosis by exercise training in obese mice: the role of sterol regulatory element-binding protein-1c. Life Sci. 2012; 91: 395-401.
35. Rector RS, Thyfault JP, Morris RT, et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol. 2008; 294: G619-26.
36. Bultot L, Guigas B, Von Wilamowitz-Moellendorff A, et al. AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase. Biochem J. 2012; 443: 193-203.
37. Van der Heijden GJ, Toffolo G, Manesso E, et al. Aerobic exercise increases peripheral and hepatic insulin sensitivity in sedentary adolescents. J Clin Endocrinol Metab. 2009; 94: 4292-9.
38. Hu X, Duan Z, Hu H, et al. Proteomic profile of carbonylated proteins in rat liver: exercise attenuated oxidative stress may be involved in fatty liver improvement. Proteomics. 2013; 13: 1755-64.
39. Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012; 57: 157-66.
40. Sullivan S, Kirk EP, Mittendorfer B, et al. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatol Baltim Md. 2012; 55: 1738-45.
41. Fu T, Choi SE, Kim DH, et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. Proc Natl Acad Sci USA. 2012; 109: 16137-42.
42. Yamada H, Suzuki K, Ichino N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013; 424: 99-103.
43. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8: 467-77.
44. Luo XJ, Tang DG, Gao TL, et al. MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of Sox4. Cell Physiol Biochem. 2014; 34: 2180-8.
45. Luo J, Meng C, Tang Y, et al. miR-132/212 cluster inhibits the growth of lung cancer xenografts in nude mice. Int J Clin Exp Med. 2014; 7: 4115-22.
46. Jiang X, Chen X, Chen L, et al. Upregulation of the miR-212/132 cluster suppresses proliferation of human lung cancer cells. Oncol Rep. 2015; 33: 705-12.
47. Borrego-Diaz E, Powers BC, Azizov V, et al. A potential regulatory loop between Lin28B:miR-212 in androgen-independent prostate cancer. Int J Oncol. 2014; 45: 2421-9.
48. Wei LQ, Liang HT, Qin DC, et al. MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. Tumour Biol. 2014; 35: 12427-34.
49. Incoronato M, Urso L, Portela A, et al. Epigenetic regulation of miR-212 expression in lung cancer. PLoS One. 2011; 6: e27722.
50. Kumarswamy R, Volkmann I, Beermann J, et al. Vascular importance of the miR-212/132 cluster. Eur Heart J. 2014; 35: 3224-31.
51. Ucar A, Gupta SK, Fiedler J, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. 2012; 3: 1078.
52. Gimeno RE, Moller DE. FGF21-based pharmacotherapy-potential utility for metabolic disorders. Trends Endocrinol Metab. 2014; 25: 303-11.
53. Cheung BM, Deng HB. Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases. Expert Rev Cardiovasc Ther. 2014; 12: 659-66.
54. Kim KH, Lee MS. FGF21 as a stress hormone: the roles of FGF21 in stress adaptation and the treatment of metabolic diseases. Diabetes Metab J. 2014; 38: 245-51.
55. Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Mol Metab. 2014; 3: 221-9.
56. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149: 6018-27.
57. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009; 58: 250-9.
58. Xu J, Stanislaus S, Chinookoswong N, et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab. 2009; 297: E1105-14.
59. Hecht R, Li YS, Sun J, et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS One. 2012; 7: e49345.
60. Véniant MM, Komorowski R, Chen P, et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology. 2012; 153: 4192-203.
61. Yang M, Zhang L, Wang C, et al. Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS One. 2012; 7: e48392.
62. Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010; 40: 887-92.
63. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010; 53: 934-40.
64. Yan H, Xia M, Chang X, et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One. 2011; 6: e24895.
65. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010; 139: 456-63.
66. Kim KH, Kim SH, Min YK, et al. Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One. 2013; 8: e63517.
67. Cuevas-Ramos D, Almeda-Valdés P, Meza-Arana CE, et al. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One. 2012; 7: e38022.